SEC Form 4 · accession 0000882796-26-000052
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alan G Levin
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 15, 2026 · 4:29 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 11, 2026 | A | 15,294 | $0.00 | A | 79,565 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Automatic Stock Option GrantF2 | $8.50 | Jun 11, 2026 | A | 33,540 | A | Jun 11, 2027 | Jun 11, 2036 | Common Stock | 33,540 | 33,540 | D |
Explanation of responses
- F1Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
- F2Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.